logo
What to know about sunscreen, SPF and protecting yourself from the sun all year round

What to know about sunscreen, SPF and protecting yourself from the sun all year round

For many Australians, the first port of call for sun safety is sunscreen.
However, a new Choice report found 16 from a sample of 20 widely available sunscreen products failed to meet the SPF level on their label.
But experts say there's no need to panic.
Here's everything they say you need to know — from how sunscreen is tested, what to look out for when shopping and what else you can do to protect yourself from the sun.
SPF stands for Sun Protection Factor — how well something protects you against ultraviolet radiation (UV).
The higher the number, the less UV passes through to your skin.
SPF measures how much time it takes for an individual to burn while wearing a particular sunscreen.
If someone normally burns after 10 minutes in the sun, an SPF of 10 should allow them to spend 100 minutes in the sun before burning, says Melanoma Institute dermatologist Dr Linda Martin.
In percentages, that means the difference between an SPF50 and SPF30 might not be as much as you think.
If applied correctly, an SPF50 lets through just 2 per cent of UV rays, whereas an SPF30 allows 3.3 per cent through, Dr Martin says.
But Michelle Wong*, a cosmetic chemist and science communicator, says the gap in effectiveness grows, the less you apply.
"So instead of just 2 per cent or 3.3 per cent of UV getting in, you will be getting either 4 per cent or 6.7 per cent," she said.
Most of us only apply around a quarter of what is used in testing conditions, Dr Martin says.
An SPF rating is calculated through testing on humans in an accredited laboratory.
It can't be done in the sun because the conditions would be variable and dangerous. Instead, an instrument called a solar simulator that imitates sunlight is used.
Researchers measure the time it takes for the skin to redden in an area where sunscreen has been applied, versus an area that has no sunscreen on it.
Australia follows the international standard for sunscreen testing, which mandates testing on 10 volunteers.
Many sunscreen brands sold in Australia test in labs overseas.
In most cases, yes — sunscreens are very effective and the Choice results shouldn't make you lose faith, Dr Wong says.
Australia has some of the strictest sunscreen regulations in the world and all are regulated by the Therapeutic Goods Administration (TGA).
But the TGA says SPF results can vary between different laboratories because of the reliance on human testing.
For example, Dr Wong says the redness of skin can be interpreted differently by testing staff, and results can differ depending on ethnicity and where testing is done.
"Someone in Australia that's just come out of our summer is also going to have much more sun-tolerant skin than someone in, let's say, Europe," she says.
Dr Wong said the best one is the one you will apply generously and regularly, and fits in with your budget.
She says most of the time, an SPF30 is going to provide enough protection if you apply the right amount.
The higher the SPF, the better — but remember if you only apply a quarter of the right amount of SPF50, you're essentially wearing an SPF 12.5, Dr Wong says.
The TGA says SPFs in the range of 30 to 59 provide "high protection", while a SPF of 60 or higher provides "very high" protection.
While SPF filters what's called UVB rays, you also need to protect from UVA radiation.
UVB rays typically causes sunburn, while UVA penetrates deeper into the skin and can get through glass.
So, make sure your sunscreen says something like 'UVB and UVA protection' or 'broad spectrum'.
Also, if you're going to be spending a lot of time in the water (or just sweating heaps) then go for a water-resistant sunscreen.
Dr Wong said there's a lot of debate about chemical versus mineral sunscreens, but at the end of the day they offer similar protection.
You'll know you have a chemical sunscreen if the ingredients include things like octocrylene or aobenzone. You'll see zinc oxide or titanium oxide if it's a mineral sunscreen.
She says in general, chemical sunscreens are lighter but have a higher chance of stinging your eyes, while mineral ones will have a more matte texture but may leave more white residue.
Sunscreen can be applied underneath moisturisers and make-up, but Dr Wong says research shows they can be more effective when put over the top of skincare.
The general recommendation is that when the UV index is forecast to reach 3 or above you should apply sunscreen as part of your daily routine.
While UV radiation is generally higher in summer than winter, it's still there all year round.
You might even need to wear sunscreen indoors, depending on your circumstances.
For example, if you spend a lot of time driving, remember that untinted windows don't completely block UVA radiation.
However, the latest advice, which you can read here and is backed by the Australasian College of Dermatologists, reflects the fact that people with darker skin tones need different sun safety advice.
There's a lot we could cover here, but the most common mistakes are:
You remember slip, slop, slap, right?
Since that campaign was rolled out in 1981, two more have been added: seek shade and slide on sunglasses.
In full, the Melanoma Institute's five rules for greater sun protection are:
"Remember sunscreen is a filter. It's not a coat of armour and it's not the only step," Dr Martin says.
"Skin cancer is the most common, the most expensive and the most preventable cancer in Australia."
*Michelle Wong says in 2022 she did one-off sponsored posts with some of the brands tested by CHOICE.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Can romantic relationships survive without sex?
Can romantic relationships survive without sex?

ABC News

time29 minutes ago

  • ABC News

Can romantic relationships survive without sex?

How often a couple has sex will fluctuate in most relationships, but what happens when it stops altogether? How one defines a 'sexless marriage' or relationship will vary. But whether it's no sex or infrequent sex over an extended period, couples lacking intimacy is "more common than many think", says Armin Ariana, a sexologist and president of the Society of Australian Sexologists Queensland branch. "This is especially notable in long-term relationships, where sexual activity often declines over time," Dr Ariana says. One Australian study found almost 15 per cent of couples hadn't engaged in sex in the past four weeks. While it's possible people in a relationship might both be comfortable with sex being off the table, a mismatch in desire is more likely at the root of why intimacy is missing, says sexologist and relationship counsellor Tanya Koens, based in the Northern Rivers/Bundjalung Nation. While talking about sex is the first step to reintroducing it, it isn't always easy. "I see people that have been together 30, 40 years, and seen each other throwing up and going through all sorts of terrible situations, and yet they will not talk about sex," says Ms Koens. Sexless relationships can arise for many reasons, both by choice and circumstance, says Brisbane/Meanjin-based Dr Ariana. Desire discrepancy is one of the most common issues he sees for decline in intimacy. "If both partners are on the same page and genuinely OK without [sex], that's not a crisis. "But when one wants connection and the other's switched off, that gap creates real tension." He says it can lead to feelings of frustration, distance and rejection. Other reasons sex may drop off include: No sex or low frequency sex can also be due to body changes including physical pain and disability, adds Ms Koens. Psychotherapist and relationship coach Tracey Rovere from Wollongong/Woolyungah says the less sex a person has, the less they tend to want it. But sex has benefits, she says. "People have sex because it makes them feel good, so they are missing out on getting the oxytocin and the different hormones released during sex." In some cases, couples may choose "to step away from sex", says Dr Ariana, for a variety of reasons. "And they can still have really strong, connected relationships. It's not always about dysfunction; sometimes it's a conscious, mutual decision that works for them." But research shows sexless couples are rarely mutually satisfied with the arrangement. A 2025 study published in the Journal of Family Psychology involving more than 2,100 heterosexual couples found that only 2.3 per cent were both sexless and mutually satisfied. "That doesn't mean it's wrong or impossible — it just means it takes strong alignment and communication to make it work," Dr Ariana says. In seeing couples who aren't having sex, Ms Koens says she approaches it with curiosity. "Why we are saying no to sex? Is it because it's too hard to talk about, or prioritise?" She says "avoidance is a number one strategy" for people not wanting to address issues there might be around sex in the relationship. For those wanting to reignite the spark and have more sex, Ms Koens says to start by focusing on what is possible. She says sex shouldn't be defined as intercourse, because there are many other ways to "have sex" and be intimate without penetration. "Your skin is an erogenous zone, you can be making out on the sofa, dry humping, just doing a bit of heavy petting and then stop. Couples should talk about "what is on the agenda" for that day. Is it just kissing? Or is it giving one person a massage? Is it penetration? "Often people assume, if my husband kisses me then I have to do all the sexual things and I don't feel like it — no," Ms Koens says. "Even just a kiss keeps physical connection." Ms Rovere says for some couples, sex may help establish more of an emotional connection, but others may need the latter first. "Connecting through sex can be a great way to reinvigorate the relationship, whereas other people think 'get the emotional connection back on track, then work towards intimacy and sexual connection'." Dr Ariana says if you're in a sexless relationship and feeling alone, "it's not a failure". "It's a signal to talk, reconnect, or reach out for support. "There's no one-size-fits-all here. What matters is whether it works for you."

Scott Power: ASX stocks fall as investors hear mixed news from Cochlear
Scott Power: ASX stocks fall as investors hear mixed news from Cochlear

News.com.au

time36 minutes ago

  • News.com.au

Scott Power: ASX stocks fall as investors hear mixed news from Cochlear

ASX heath sector falls 1.1% over past five days, while broader markets flat as Middle East tensions flare Cochlear downgrades full-year profit expectations but launches a world first Monash IVF head Michael Knaap resigns after another embryo mix-up Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. It was a big week of news for the ASX healthcare sector with the bourse's fourth largest biotech Cochlear (ASX:COH) downgrading its FY25 net earnings ~4% to $390-400 million, compared with prior guidance in February of $410-430m, on "slower-than-expected sales growth over the last few months". Morgans' healthcare analyst Derek Jellinek wrote in a note to clients consensus for the hearing tech company sat at $411m with Morgans at $412m. While Cochlear continues to expect implant units to grow ~10% in FY25, growth will be weighted to emerging markets as developed market growth has been impacted by slower-than expected market growth and a "small loss" of market share in a few countries. Cochlear now expects services revenue to decline by low double-digits compared to prior expectations for a single-digit decline. "COH believes ongoing work to identify and connect with recipients who could benefit from the latest sound processing technology, combined with the introduction of the new off-the-ear Nucleus Kanso 3 sound processor, which is expected to launch in EU and APAC mid-Jun-25, should lift services revenue in FY26," Jellinek wrote. Following a disappointing H1 FY25 result, Morgans highlighted risks in the services segment (around 25% of sales), driven by slower-than-expected uptake of the Nucleus 8 sound processor, which was launched in FY23, and cost-of-living pressures delaying device replacements. But in some positive news, Cochlear also announced the launch of Nucleus Nexa, the world's first and only smart cochlear implant system, saying it was the "outcome of a 20 year investment in R&D". "A couple of key features include upgraded firmwear, the smallest sound processor and internal memory so that has actually countered the profit downgrade they've announced," Power said. Morgans has a hold rating on Cochlear with a 12-month target price of $285.55. Monash chief quits following another embryo mixup A new acting CEO has been appointed to steer the troubled Monash IVF Group (ASX:MVF), which fell ~27% on Tuesday after reporting another embryo implant bungle. Monash announced on Thursday CEO and managing director Michael Knaap had resigned with CFO and company secretary Malik Jainudeen appointed acting CEO. In the latest incident a patient's own embryo was mistakenly transferred to them, rather than their partner's embryo as specified in the treatment plan at Monash's Clayton laboratory in Melbourne on June 5. Monash said it was conducting an internal investigation to determine the cause of the incident and notified the relevant assisted reproductive technology (ART) regulators, the Victorian health regulator and its insurers. It comes after Monash revealed in April a woman had given birth to a baby that was not hers after receiving the wrong embryo at a Brisbane clinic. An independent review by Fiona McLeod AO SC regarding that incident is currently ongoing and has been extended, with the findings yet to be disclosed. Monash confirmed that its updated profit guidance, issued on May 20, remains unchanged, projecting an underlying NPAT of $27.5 million. Morgans maintains a speculative buy on Monash with a 12-month target price of $1. Israel strikes on Iran add to market uncertainty At 1.45pm on Friday the S&P/ASX 200 Health Care index was down 1.1% for the past five days, while the benchmark ASX 200 was flat for the same period. Markets took a tumble on Friday after reports of Israel strikes against Iran's nuclear sites with the Middle East bracing for retaliation. Power said the escalating conflict adds further complexity to global equity markets still very much being driven by macroeconomic factors and geopolitical tensions. "Markets are still very much broader macro driven including with US President Donald Trump's trade and regulatory policies," Power said. "Investors will now be closely monitoring the escalating tensions in the Middle East." Power's Powerplay: EBR completes raise, starts US rollout EBR Systems (ASX:EBR) is Power's stock of the week after announcing completion of a share purchase plan (SPP) and that the first US commercial patients have been implanted with its WiSE CRT System, the world's only wireless solution for pacing the left side of the heart. The procedures took place at St David's Medical Centre and the Cleveland Clinic, two of several leading US institutions participating in this pilot release of the WiSE CRT System, which was approved by the FDA in April. EBR said the cases represented two of the main indications for WiSE. "Clearly, the first commercial patients implanted with WiSE is a key milestone, as EBR has officially transitioned from a pure R&D focus to a commercial entity," Jellinek wrote in a note to clients. He said importantly, the implants were done in advance of reimbursement and the limited market release of WiSE, which remained on track for October, showcasing the unmet medical need in the initial US$3.6m total addressable market and belief in use of the device. "As this device is a novel treatment option requiring physician education, we view the LMR, targeting key heart failure centres in the US, as an appropriate strategic way to build familiarity and experience, prior to full market release," he wrote. "We see sales surpassing US$80m into CY29. "While certainly not a 'hockey stick', we believe it is a methodical, stage-gated rollout to build strong physician support and closely monitor clinical outcomes, helping to pique interest from any would-be suitor." The company also announced today it had finished its SPP raising $xxm and adding to a fully underwritten Institutional Placement raising $55.9m completed in May. Proceeds from the capital raise will be used to advance its US commercialisation strategy for WiSE. Morgans has a buy rating and 12-month target price of $2.86. Two positive studies for Avita Wounds management company Avita Medical (ASX:AVH) has announced the first clinical publication of its Cohealyx product, which is a collagen-based dermal matrix, in the Journal of Surgery. The publication includes two positive case reports on patients with complex hand wounds treated with Cohealyx. In both instances, the patients sustained full-thickness burns following syncopal episode (temporary loss of consciousness due to a drop in blood flow to the brain). The study showed significant acceleration of wound bed vascularisation and autograft readiness, achieving readiness within five to 10 days compared to the typical two to four weeks. "Clearly, a small sample size and this publication represents the first clinical validation of AVH's preclinical findings but it's a strong start and likely the first of many case-studies to come," Morgans' healthcare analyst Iain Wilkie wrote in a note to clients Avita also announced a new study of its flagship spray-on skin treatment Recell showed it reduced hospital stays by 36% compared to traditional skin grafts. Presented at the British Burn Association's annual meeting, the US-based study analysed outcomes for more than 6,300 patients treated with Recell between 2019 and 2024. All patients had burns covering less than 30% of their total body surface area. The findings showed Recell patients spent on average 6.2 fewer days in hospital, delivering an estimated $300m in healthcare savings over the five-year period. Wilkie wrote that the share price had continued to remain weak following series of missed guidance expectations and dwindling cash reserves. "The point with Avita is they've expanded their product range to treat more of the wound complex and what the market is concerned about is do they need to raise additional funds," Power said. "They've told the market they can see a pathway through to profitability or breakeven by the fourth quarter of this calendar year so as each quarter rolls on we will get more confident that they're able to achieve that." Morgans has a speculative buy rating on Avita and 12-month target price of $3.76. Imricor gets CE Mark for NorthStar Mapping System Imricor Medical Systems (ASX:IMR) has received CE mark (European) certification for its NorthStar Mapping system under the new, more stringent European Union Medical Device Regulations (MDR). NorthStar has been approved as a Class IIa medical device with the certification received ahead of schedule. Imricor is advancing technology for real-time interventional cardiac magnetic resonance (iCMR) ablations, enabling cardiac ablation procedures to be guided by live MRI imaging instead of traditional x-ray fluoroscopy. NorthStar is a key component of its product offering. The certifications follows on from recent European approvals received for its Advantage-MR EP Recorder/Stimulator (Advantage-MR), and its second generation Vision-MR Ablation Catheter. "Imricor will now phase out first generation products approved under the old EU regulations, replacing them with new MDR approved devices," Power said. "We expect sales momentum to steadily build over coming quarters." Power said next catalysts to watch for include additional sales orders in Europe and Middle East and US FDA approval for NorthStar. Imricor is also undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial to support FDA approval of its products, which it hopes to achieve in 2025. In Europe, where Imricor has already received regulatory approval for atrial flutter, the company has started a pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT). Morgans has a speculative buy on Monash and 12-month $2.28 target price. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.

ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis
ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis

ABC News

time2 hours ago

  • ABC News

ABC Radio Sydney presenter James Valentine announces omentum cancer diagnosis

I'd really hoped I'd never have to do this again. I've now twice gone on the radio on 702 ABC Sydney, and published articles online, revealing details of my disease. In March 2024, I announced that I had oesophageal cancer, and I was heading off for major surgery and it might be a while before I'd be back. In September 2024, I came back on air, and let everyone know, that I'd had a more minor procedure, removed the tumour in my oesophagus and would then be monitored for any future outbreaks. Well, here in June 2025, I'm telling you the monitoring works very well. My current scans, and a biopsy have confirmed that I have tumours in my omentum. Yes, omentum, I'd never heard of it either. It's described usually as a fatty veil, which extends from the stomach over your intestine. Quite what it does, not sure; partly packaging, partly helping to protect the intestine, possibly some role in dealing with infection. Whatever it's meant to do it is currently largely squeezing my bowel and causing constriction and constipation and general discomfort in that part of the world. Oh, it's been a fun few weeks, my friends. I am now way too familiar with the 'digestive' aisle of my local chemist. So I've been off the last couple of weeks, getting tests, and figuring out what's to be done. As of next week, I will be beginning chemotherapy and immunotherapy. A big blast of 21st century science, that hopefully, will scour it all out and leave me in a position to heal and recover. Immunotherapy is the great hope of everyone these days. I'm eligible, as in it's considered that it's very likely to be effective in my case. I won't be able to keep working so I'll be off air now for at least three months. Side effects of the treatment range from mildly irritating to horrendous, so I think I'll just deal with them. Best I focus on this one thing, and give the medicine and the process its best chance. I've been back playing saxophone and doing some gigs and some live theatre shows as well which, from my point of view on the stage, have been wonderful! So they too will be put on hold for a while until this cancer has abated. Back when this cancer was just a tumour in short pants in my oesophagus I was faced with a choice between the full removal of my oesophagus or the removal of only the tumour, leaving my oesophagus intact. I accepted then that I was making the decision on what I would do. The difficulty with the decision was that both doctors were right; the full surgery was more common and the accepted protocol for my condition, but the lesser procedure was possible. The way I often expressed it then and since, has been to say that I chose a different set of risks. To remove the oesophagus fully was likely to leave me with a long recovery and a potential set of morbidities and difficulties in living that would be challenging. To remove the tumour was to accept that I'd be initially OK, but cancer could return. In fact, in both procedures there was always the likelihood of future cancer. The future's arrived. There may be debate as to whether the full removal might have prevented this, but given that the initial tumour may have been there for a while, undetected and asymptomatic, there's every chance that cancer cells have been out in my body for some time, looking for a place to call home, and the full surgery would not have prevented their spread. I'm not that concerned about that, the how, the why, the might have been. I find cancer, like any other major insult to my being, has a way of bringing me very firmly into the present. What's happening to me, what can I do to fix this, what do I need to do right now this day, this hour, this minute? That's me for the next few months. Treatment, deal with the treatment, rest, build strength for next treatment. In between, be with the people I love. I'm already missing you, I'm already wanting to get back on air. All is not right unless I'm on the radio in the afternoon and there's Rant, and Petty Crimes being solved and couples sharing on This Is What I Live With and all the other glorious, revealing, hilarious and shambolic conversations we share every day. I don't pray, but if you do, please go hard. I can feel your good wishes, love and support and I thank you deeply for it. When I know anything about what's happening, I'll let you know but right now I'm off to the land of the sick. When I get back, you'll hear from me.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store